Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.56 |
| ▸ | MGAM | O43451 | 15/20 | 0.56 |
| ▸ | GAA | P10253 | 15/20 | 0.56 |
| ▸ | SI | P14410 | 15/20 | 0.56 |
| ▸ | MGAM2 | Q2M2H8 | 15/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | CBFB | Q13951 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5318091 | 0.98 | PARP1 (0.55) | PARP1MGAMGAASIMGAM2 | |
| SCHEMBL20936149 | 0.83 | PARP1 (0.56) | PARP1MGAMGAASIMGAM2 | |
| SCHEMBL1170892 | 0.83 | MGAM (0.71) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL4692683 | 0.79 | MGAM (0.53) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL727228 | 0.79 | MGAM (0.53) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL3109602 | 0.79 | MGAM (0.60) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL6139625 | 0.79 | MGAM (0.60) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL3424862 | 0.79 | MGAM (0.60) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL17801881 | 0.79 | MGAM (0.53) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL110724 | 0.79 | MGAM (0.53) | MGAMGAASIMGAM2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344630-B2 | Novel, heavy vitamin B12 derivatives | CHARLES STURT UNIVERSITY (AU) | 2025-07-01 | — | — | US | claimed |
| US-20240368659-A1 | MICROBIAL CELL FACTORIES PRODUCING VITAMIN B COMPOUNDS | BIOSYNTIA APS (DK) | 2024-11-07 | — | — | US | claimed |
| CN-118079660-A | Preparation method and application of zeolite-imidazole ester framework material film | 中国科学院大连化学物理研究所 | 2024-05-28 | — | — | CN | claimed |
| EP-4370653-A2 | MICROBIAL CELL FACTORIES PRODUCING VITAMIN B COMPOUNDS | Biosyntia ApS (DK) | 2024-05-22 | — | — | EP | claimed |
| US-20240101591-A1 | NOVEL, HEAVY VITAMIN B12 DERIVATIVES | CHARLES STURT UNIVERSITY (AU) | 2024-03-28 | — | — | US | claimed |
| EP-4331561-A1 | USE OF ORAL CARE COMPOSITION | Unilever IP Holdings B.V. (NL) | 2024-03-06 | — | — | EP | claimed |
| CN-117524740-A | 3D printing zinc vanadate/carbon nano composite electrode and preparation method and application thereof | 中国科学院福建物质结构研究所 | 2024-02-06 | — | — | CN | claimed |
| US-11884695-B2 | Heavy vitamin B12 derivatives | CHARLES STURT UNIVERSITY (AU) | 2024-01-30 | — | — | US | claimed |
| CN-116364907-B | Lithium-rich manganese-based layered cathode material, and preparation method and application thereof | 天津巴莫科技有限责任公司 | 2023-08-29 | — | — | CN | claimed |
| CN-116364907-A | Lithium-rich manganese-based layered cathode material, and preparation method and application thereof | 天津巴莫科技有限责任公司 | 2023-06-30 | — | — | CN | claimed |
| EP-0906430-B1 | BIOSYNTHESIS METHOD ENABLING THE PREPARATION OF O-PHOSPHO-L-THREONINE | AVENTIS PHARMA SA (FR) | 2006-07-26 | — | — | EP | claimed |
| US-20060110322-A1 | Assay for vitamin B12 absorption and method of making labeled vitamin B12 | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-05-25 | — | — | US | claimed |
| US-6329536-B1 | REACTING UNSATURATED NITROOLEFIN COMPOUND WITH BETA-DICARBONYL COMPOUND IN THE PRESENCE OF A CATALYST COMPLEX AND A BASE, CATALYST COMPLEX COMPRISING A LIGAND AND A METAL COMPLEX | ABBOTT LABORATORIES | 2001-12-11 | — | — | US | claimed |
| EP-1114022-A1 | PROCESS FOR PRODUCING STEREOSELECTIVE NITRO COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-07-11 | — | — | EP | claimed |
| WO-2000015599-A1 | PROCESS FOR PRODUCING STEREOSELECTIVE NITRO COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-03-23 | — | — | WO | claimed |
| US-5968708-A | METAL PHTHALOCYANINE WITH MANGANESE, IRON, COBALT, ZINC OR CADMIUM METAL WITH ETHER OR SULFIDE SUBSTITUENTS | RICOH COMPANY, LTD. (JP) | 1999-10-19 | — | — | US | claimed |
| EP-0906430-A1 | BIOSYNTHESIS METHOD ENABLING THE PREPARATION OF COBALAMINS | Aventis Pharma S.A. (FR) | 1999-04-07 | — | — | EP | claimed |
| WO-1997043421-A1 | BIOSYNTHESIS METHOD ENABLING THE PREPARATION OF COBALAMINS | RHONE-POULENC RORER S.A. (FR) | 1997-11-20 | — | — | WO | claimed |
| CN-1054799-A | The relevant polypeptide of biosynthesizing cobalami and/or cobamide, dna sequence dna, its preparation method and the application of these polypeptide of encoding | RHONE POULENC BIOCHIMIE (FR) | 1991-09-25 | — | — | CN | claimed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344630-B2 | Novel, heavy vitamin B12 derivatives | HMBS, SLC19A1, SLC19A2 | PARP1 4434/4885MGAM 3372/4885GAA 3098/4885 |
| US-20240101591-A1 | NOVEL, HEAVY VITAMIN B12 DERIVATIVES | HMBS, SLC19A1, SLC19A2 | PARP1 4434/4885MGAM 3372/4885GAA 3098/4885 |
| US-11884695-B2 | Heavy vitamin B12 derivatives | HMBS, SLC19A1, SLC19A2 | PARP1 4226/4885MGAM 2691/4885GAA 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.